A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

NCT05105607 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration
Diabetic Macular Edema

Interventions

DRUG: D-4517.2

Sponsor

Ashvattha Therapeutics, Inc.